Batchelor TT, Gerstner ER, Ye X, Desideri S, Duda DG, Peereboom D, Lesser GJ, Chowdhary S, Wen PY, Grossman S, Supko JG. Feasibility, phase I, and phase II studies of tandutinib, an oral platelet-derived growth factor receptor-ß tyrosine kinase inhibitor, in patients with recurrent glioblastoma. Neuro Oncol. 2017 04 01; 19(4):567-575.